Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of metformin + axitinib in BRAF-mutant advanced melanoma
2011-001793-26Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin and axitinib in melanoma, sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Primary efficacy of metformin + axitinib. Started Sep 2011; status: completed.
02
Drugs
metforminaxitinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-001793-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001793-26.